| HOME | HELP | E-MAIL ALERTS | SEARCH |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POLICY STATEMENT |
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This statement provides revised recommendations for administering RSV prophylaxis to infants and children with congenital heart disease, for identifying infants with a history of preterm birth and chronic lung disease who are most likely to benefit from immunoprophylaxis, and for reducing the risk of RSV exposure and infection in high-risk children. On the basis of results of a recently completed clinical trial, prophylaxis with palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks’ gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present. High-risk infants should not attend child care during the RSV season when feasible, and exposure to tobacco smoke should be eliminated.
Abbreviations: RSV, respiratory syncytial virus • RSV-IGIV, Respiratory Syncytial Virus Immune Globulin Intravenous • CLD, chronic lung disease • CHD, congenital heart disease
Related Article
The following policy statements have been revised:
Statement of retirement:
This article has been cited by other articles:
 |
|
 |
|
  R. Carbajal, V. Biran, R. Lenclen, R. Epaud, P. Cimerman, P. Thibault, D. Annequin, F. Gold, and B. Fauroux EMLA Cream and Nitrous Oxide to Alleviate Pain Induced by Palivizumab (Synagis) Intramuscular Injections in Infants and Young Children Pediatrics, June 1, 2008; 121(6): e1591 - e1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Lorch, A. M. Millman, X. Zhang, O. Even-Shoshan, and J. H. Silber Impact of Admission-Day Crowding on the Length of Stay of Pediatric Hospitalizations Pediatrics, April 1, 2008; 121(4): e718 - e730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Section on Surgery and the Committee on Fetus and Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia Pediatrics, March 1, 2008; 121(3): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Khemani, D. B. McElhinney, L. Rhein, O. Andrade, R. V. Lacro, K. C. Thomas, and M. P. Mullen Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era Pediatrics, December 1, 2007; 120(6): 1260 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Awomoyi, P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. G. Blanco, and S. N. Vogel Association of TLR4 Polymorphisms with Symptomatic Respiratory Syncytial Virus Infection in High-Risk Infants and Young Children J. Immunol., September 1, 2007; 179(5): 3171 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Broughton, A Roberts, G Fox, E Pollina, M Zuckerman, S Chaudhry, and A Greenough Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants Thorax, December 1, 2005; 60(12): 1039 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Prais, D. Danino, T. Schonfeld, J. Amir, and for the Israeli RSV Monitoring Group Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey{dagger} Chest, October 1, 2005; 128(4): 2765 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N D Embleton, C Harkensee, and M C Mckean Palivizumab for preterm infants. Is it worth it? Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2005; 90(4): F286 - f289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhao and W. M. Sullender In Vivo Selection of Respiratory Syncytial Viruses Resistant to Palivizumab J. Virol., April 1, 2005; 79(7): 3962 - 3968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mejias, S. Chavez-Bueno, and P. J. Sanchez Respiratory Syncytial Virus Prophylaxis NeoReviews, January 1, 2005; 6(1): e26 - e31. [Full Text] [PDF]
|
|
|
|
|
|
S. Wegner, J. J. Vann, G. Liu, P. Byrns, C. Cypra, W. Campbell, and A. Stiles Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program Pediatrics, December 1, 2004; 114(6): 1612 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Meissner, L. J. Anderson, and L. K. Pickering Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab Pediatrics, October 1, 2004; 114(4): 1082 - 1084. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Meissner and M. B. Rennels Unpredictable Patterns of Viral Respiratory Disease in Children Pediatrics, June 1, 2004; 113(6): 1814 - 1816. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Meissner, S. S. Long, and Committee on Infectious Diseases, and Committee on Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections Pediatrics, December 1, 2003; 112(6): 1447 - 1452. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | E-MAIL ALERTS | SEARCH |
